Modulation of reactivation of a latent virus

1. A method of reducing latent virus in an individual, the method comprising:

(i) administering a therapeutically effective amount of one or more agents to the individual that:

(a) inhibits activity of signal transducer and activator of transcription 3 (STAT3), or

(b) activates any of p300, CBP, or p300/CBP; wherein the one or more agents promotes reactivation of the latent virus, and

(ii) administering a therapeutically effective amount of an antiviral agent to the individual, thereby reducing latent virus in the individual, wherein the latent virus is a herpes virus, a human cytomegalovirus, or a human immunodeficiency virus.

2. The method of claim 1 , wherein the one or more agents that inhibits activity of STAT3 is selected from the group consisting of cucurbitacin I, niclosamide, cryptotanshinone, SD 1008, (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide (Stat3 Inhibitor III), WP1066, Nifuroxazide, Stattic, S3I-201; 5,15-Diphenyl-21H,23H-porphine (Stat3 Inhibitor VIII), 5,15-DPP, 2-Hydroxy-4-(((4-methylphenyl)sulfonyloxy)acetyl)amino)-benzoic acid (NSC74859) and Kahweol.

3. The method of claim 2 , wherein the one or more agents that activates any of p300, CBP, or p300/CBP is MSG I.

4. The method of any one of claims 1 - 3 , further comprising administering a therapeutically effective amount of one or more HDAC inhibitory agents that inhibits the activity of a histone deacetylase (HDAC), wherein inhibition of the activity of the HDAC by the one or more HDAC inhibitory agents promotes reactivation of the virus.

5. The method of claim 4 , wherein the one or more HDAC inhibitory agents is selected from the group consisting of sodium butyrate, vorinostatin (SAHA), valproic acid, trichostatin A (TSA), (3aR,6S,9S,12S)-9,12-Dibenzyl-6-[6-oxo-6-[(S)-oxiranyl]hexyl]-1,2,3,3a,8,9-hexahydro-5,8,11,13a-tetraaza-13aH-cyclopentacyclododecene-4,7,10,13(5H,6H,11H,12H)-tetrone (trapoxin B), phenylbutyrate, valproic acid, (2E)-N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide (belinostat PXD101), (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (LAQ824), (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide (panobinostat LBH589), Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate (entinostat, MS-275), 4-(Acetylamino)-N-(2-aminophenyl)benzamide (CI994), (E)-3-(4-((E)-3-(3-fluorophenyl)-3-oxoprop-1-enyl)-1-methyl-1H-pyrrol-2-yl)-N-hydroxyacrylamide (MC1568) and N-(2-Aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide (mocetinostat, MGCD0103).

6. A method of inhibiting reactivation of a virus in an individual, the method comprising:

administering a therapeutically effective amount of one or more agents to the individual that:

(a) activates signal transducer and activator of transcription 3 (STAT3), or

(b) inhibits any of p300, CBP, or p300/CBP;

wherein the one or more agents inhibits reactivation of the virus, and wherein the virus is a herpes virus, a human cytomegalovirus, or a human immunodeficiency virus.

7. The method of claim 6 , wherein the one or more agents that activate STAT3 is selected from the group consisting of an interferon, epidermal growth factor, interleukin-5, interleukin-6, interleukin-10, hepatocyte growth factor, leukemia inhibitory factor, bone morphogenetic protein 2 and leptin.

8. The method of claim 7 , wherein the one or more agents that inhibit any of p300, CBP, or p300/CBP is selected from the group consisting of 2-(3,4,5-Trihydroxyphenyl)chromenylium-3,5,7-triol (delphinidin), 4-[4-[[5-(4,5-Dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]benzoic acid (C646), (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione (curcumin), (1R,5R,7R)-3-(3,4-Dihydroxybenzoyl)-4-hydroxy-8,8-dimethyl-1,7-bis(3-methyl-2-buten-1-yl)-5-[(2S)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]-Bicyclo[3.3.1]non-3-ene-2,9-dione (garcinol), and 2-Hydroxy-6-pentadecylbenzoic acid anacardic acid).

9. The method of any one of claims 6 - 8 , further comprising administering a therapeutically effective amount of one or more HDAC activating agents that activates a histone deacetylase (HDAC), wherein activation of the HDAC by the one or more agents inhibits reactivation of the virus.

10. The method of claim 9 , wherein the one or more HDAC activating agents is ITSA1 (N-(1H-Benzotriazol-1-yl)-2,4-dichlorobenzamide).

11. The method of claim 1 , wherein the herpes virus is herpes simplex virus 1 (HSV-1) or herpes simplex virus 2 (HSV-2).